The system is designed to enhance laboratory workflow for improved efficiency and faster results
United Arab Emirates - Beckman Coulter, one of the world’s leading clinical diagnostics companies, today announced the launch of its DxN VERIS Molecular Diagnostic System in the United Arab Emirates. The platform is expected to set a new standard in molecular diagnostics testing by revolutionizing workflow automation and improving laboratory outputs.
The launch enables Beckman Coulter Diagnostics to bring its 80-year legacy of automation and innovation in the clinical diagnostics laboratory to the molecular diagnostics arena, supporting the company’s mission of moving healthcare forward.
The DxN VERIS Molecular Diagnostics System is a fully automated, sample-to-answer instrument for the quantitative analysis of molecular targets. The unique features of the system are designed to ensure that the laboratory can run multiple diverse markers, at any given time, with minimal manual intervention. The DxN VERIS integrates sample introduction, nucleic acid extraction, reaction setup, real-time PCR amplification and detection and results interpretation in a single instrument.This integrated approach enables molecular diagnostics laboratories to provide fast and reliable test results, while improving workflow and reducing number of consumables.
“The DxN VERIS system represents a paradigm shift in molecular diagnostics,” said Ganesh Ramaswamy, senior vice-president, customer operations for high-growth markets at Beckman Coulter. “It offers a simplified, flexible and LEAN workflow that produces fast, accurate results for physicians and their patients.”
-more-
The growing menu of assays for use on the DxN VERIS Molecular Diagnostics System includes the following CE-marked products:
· VERIS CMV Assay for the quantitative determination of human Cytomegalovirus (CMV) in plasma
· VERIS HBV Assay for the quantitative measurement of Hepatitis B Virus (HBV) in human plasma and serum
· VERIS HCV Assay for the quantitative measurement of Hepatitis C Virus (HCV) in human plasma
· VERIS HIV-1 Assay for quantitative detection of Human Immunodeficiency Virus type 1 (HIV-1) in plasma
Beckman Coulter is committed to meeting the evolving needs of the medical community and aims to expand the DxN VERIS Molecular Diagnostics System menu, as well as introduce new assays currently in development.
About Beckman Coulter
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter’s instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes—offering a broad portfolio of chemistry, immunoassay, haematology, urinalysis, microbiology, automation, information systems and molecular diagnostics. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com
*DxN VERIS product line is CE marked. DxN VERIS product line has not been submitted to U.S. FDA, so not for sale or distribution in the U.S. and not available in all markets. DxN VERIS Molecular Diagnostics System is also known as VERIS Molecular Diagnostics System and VERIS MDx System.
Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.
Contact: Contact:
Alexandra Awad Monique Blom
Beckman Coulter Diagnostics, Dubai Beckman Coulter Diagnostics
+971 4550 8780 > aawad@beckman.com +41 22 365753 > mblom@beckman.com
© Press Release 2016
